NASDAQ:ASMB - Assembly Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$48.04 +1.08 (+2.30 %)
(As of 06/19/2018 04:57 AM ET)
Previous Close$46.96
Today's Range$46.46 - $48.38
52-Week Range$18.60 - $67.36
Volume97,200 shs
Average Volume187,957 shs
Market Capitalization$965.06 million
P/E Ratio-19.93
Dividend YieldN/A
Assembly Biosciences logoAssembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio9.30
Quick Ratio9.30


Trailing P/E Ratio-19.93
Forward P/E Ratio-14.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.02 million
Price / Sales109.45
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book8.55


EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-379.22%
Return on Equity-56.56%
Return on Assets-32.21%


Outstanding Shares20,550,000

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) released its quarterly earnings data on Monday, May, 7th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.12. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to analyst estimates of $1.88 million. Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. View Assembly Biosciences' Earnings History.

What price target have analysts set for ASMB?

3 analysts have issued 1-year target prices for Assembly Biosciences' shares. Their forecasts range from $45.00 to $75.00. On average, they expect Assembly Biosciences' share price to reach $56.6667 in the next twelve months. View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Richard J. Colonno Ph.D., Chief Scientific Officer (Age 68)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 62)
  • Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
  • Dr. Miguel S. Barbosa Ph.D., Strategic Advisor (Age 60)

Has Assembly Biosciences been receiving favorable news coverage?

Media headlines about ASMB stock have been trending somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Assembly Biosciences earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (5.32%), Rock Springs Capital Management LP (2.16%), Northern Trust Corp (1.09%), Lyon Street Capital LLC (0.68%), Victory Capital Management Inc. (0.60%) and JPMorgan Chase & Co. (0.53%). View Institutional Ownership Trends for Assembly Biosciences.

Which institutional investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BNP Paribas Arbitrage SA, JPMorgan Chase & Co., A.R.T. Advisors LLC, Hsbc Holdings PLC, Rock Springs Capital Management LP, California Public Employees Retirement System and EAM Global Investors LLC. View Insider Buying and Selling for Assembly Biosciences.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, venBio Select Advisor LLC, WINTON GROUP Ltd, Iguana Healthcare Management LLC, Lyon Street Capital LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $48.04.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $965.06 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]

MarketBeat Community Rating for Assembly Biosciences (ASMB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.